​​

Dynaptive™ is a pioneering AI-driven platform for de novo drug discovery, engineered to develop first-in-class small molecules that effectively target cancer both in its present state and as it evolves. By harnessing advanced AI-driven resistance modeling, Dynaptive™ accurately predicts and preempts future cancer mutations, ensuring sustained efficacy of treatments.